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ABSTRACT	
Objectives:	To	assess	the	efficacy	and	safety	of	methotrexate	(MTX)	in	combination	with	an	
approved	biological	agent	compared	to	biological	monotherapy,	in	the	management	of	patients	
with	rheumatoid	arthritis	(RA).		
Methods:	MEDLINE,	EMBASE,	CENTRAL	and	other	sources	were	searched	for	randomised	trials	
evaluating	a	biological	agent	plus	MTX	versus	the	same	biological	agent	in	monotherapy.	Co-
primary	outcomes	were	ACR50	and	the	number	of	patients	who	discontinued	due	to	adverse	
events	(AEs).	Random-effects	models	were	applied	for	meta-analyses	with	risk	ratio	and	95%	
confidence	intervals	and	the	GRADE	approach	was	used	to	assess	confidence	in	the	estimates.		
Results:	The	analysis	comprised	16	trials	(4,965	patients),	including	all	biological	agents	approved	
for	RA	except	anakinra	and	certolizumab.	The	overall	likelihood	of	responding	to	therapy	(i.e.	
ACR50)	after	6	months	was	32%	better	when	MTX	was	given	concomitantly	with	biological	
agents	(1.32	[1.20	to	1.45];	P<0.001)	corresponding	to	11	more	out	of	100	patients	(7	to	16	more);	
Moderate	Quality	Evidence.	Discontinuing	due	to	AEs	from	concomitant	use	of	MTX	was	
potentially	20%	increased	(1.21	[0.97	to	1.50];	P=0.09)	compared	to	biological	monotherapy	
corresponding	to	1	more	out	of	100	patients	(0	to	3	more);	Moderate	Quality	Evidence.	
Conclusions:	Randomised	trials	provide	Moderate	Quality	Evidence	for	a	favourable	benefit-
harm	balance	supporting	concomitant	use	of	MTX	rather	than	monotherapy	when	prescribing	a	
biological	agent	in	patients	with	RA	although	in	absolute	terms	only	7	to	16	more	out	of	100	
patients	will	achieve	an	ACR50	response	after	6	months	of	this	combination	therapy.		
Registration:	PROSPERO	identifier:	CRD42014014633.	
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INTRODUCTION	
The	primary	goal	of	therapy	in	patients	with	RA	is	to	maximise	long-term	health-related	quality	of	
life	through	control	of	symptoms,	prevention	of	structural	damage,	normalisation	of	function	and	
social	participation	(1).	Initiating	disease-modifying	anti-rheumatic	drug	(DMARD)	therapy	as	
soon	as	possible	improves	the	disease	course	and	helps	to	attain	this	goal.	
Among	the	conventional	synthetic	DMARDs	(csDMARDs),	methotrexate	(MTX)	is	
considered	the	anchor	drug	in	RA	treatment	both	in	csDMARD	naïve	patients,	as	well	as	in	
patients	treated	in	combination	with	biological	DMARDs	(bDMARDs).	The	‘American	College	of	
Rheumatology’	(ACR)	and	the	‘European	League	Against	Rheumatism’	(EULAR)	recommend	use	of	
bDMARDs	with	concomitant	use	of	MTX	in	patients	who	have	high	disease	activity	with	poor	
prognostic	features	(2;3).	The	nine	bDMARDs	currently	approved	for	RA	therapy	include:	five	
tumour	necrosis	factor	inhibitors	(TNFi)	–	adalimumab,	certolizumab	pegol,	etanercept,	
golimumab,	and	infliximab;	also	available	but	with	different	modes	of	action	are	abatacept,	
anakinra,	rituximab,	and	tocilizumab.	
Registries	of	routine	clinical	practice	treatment	indicate	that	approximately	one	
third	of	RA	patients	are	being	treated	with	a	bDMARD	in	monotherapy	(4-9).	Although	MTX	has	
one	of	the	most	favourable	efficacy:toxicity	ratios	among	the	csDMARDs	(10-13),	analyses	from	
health	care	claims	suggest	that	when	MTX	is	prescribed	in	combination	with	a	bDMARD,	more	
than	half	of	the	patients	do	not	collect	the	MTX	prescription	(14)	and	overall	patients	seem	to	
taper	MTX	intake	over	time	(15).	Despite	the	current	understanding	about	clinical	use	of	the	
combination	of	a	bDMARD	and	MTX,	the	actual	benefit-harm	associated	with	this	combination	
compared	to	bDMARD	in	monotherapy	has	not	been	evaluated	extensively.	
Our	objective	was	to	assess	the	efficacy	and	safety	of	combining	MTX	to	a	bDMARD	
compared	to	bDMARD	in	monotherapy	in	the	management	of	patients	with	RA.	Secondarily	we	
wanted	to	explore	whether	the	potentially	added	value	of	MTX	varies	across	the	different	
bDMARDs.	
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METHODS	
Study	selection,	assessment	of	eligibility	criteria,	data	extraction,	and	statistical	analyses	were	
performed,	based	on	a	predefined	protocol	(PROSPERO:	CRD42014014633)	in	accordance	with	
the	current	methodology	guidelines	(16).	The	reporting	of	the	systematic	review	and	meta-
analysis	follows	the	recommendations	from	the	PRISMA	(Preferred	Reporting	Items	for	
Systematic	reviews	and	MetaAnalyses)	statement	(17).	
Eligibility	criteria	
All	RA	randomised	controlled	trials	(RCTs)	evaluating	the	effect	of	combination	therapy	with	any	
approved	bDMARDs	and	MTX	versus	the	same	bDMARD	alone	(i.e.	bDMARD	monotherapy)	
qualified	for	inclusion.	The	bDMARDs	of	interest	included	all	currently	approved	for	RA	
(abatacept,	adalimumab,	anakinra,	certolizumab	pegol,	etanercept,	golimumab,	infliximab,	
rituximab,	and	tocilizumab).	No	restrictions	on	dose,	treatment	duration,	and	administration	
procedures	were	imposed	on	either	bDMARDs	or	MTX.	The	eligible	comparator	group	was	the	
same	bDMARD	in	the	same	dose	as	the	intervention	group	(i.e.	within	each	trial)	administered	
without	concomitant	MTX	(i.e.	bDMARD	monotherapy).	
Identification	and	selection	of	studies	
The	Cochrane	Central	Register	of	Controlled	Trials,	Medline	(via	PubMed),	Embase,	and	
ClinicalTrials.gov	were	searched	for	published	RCTs	from	inception	of	each	database	to	April	19,	
2016	(Supplement	Table	1).	Additional	RCTs	identified	in	relevant	systematic	reviews	not	
retrieved	through	the	electronic	databases	were	then	collated.	Relevant	RCTs	on	FDA's	and	
EMA's	websites,	and	relevant	pharmaceutical	companies’	websites	were	scrutinized	to	identify	
unpublished	trial	data.	Search	results	and	full-text	articles	were	independently	assessed	by	two	
reviewers	with	disagreements	resolved	through	consensus	or	referral	to	a	third	reviewer.	
Data	collection	and	study	appraisal	
A	priori	a	benefit	outcome	and	a	harm	outcome	were	selected	from	among	the	recommended	
major	outcomes	from	the	Cochrane	Musculoskeletal	Group	(CMSG)	(18).	These	co-primary	
outcomes	were	ACR50	for	benefit	(defined	as	a	50%	improvement	in	the	American	College	of	
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Rheumatology	criteria	[ACR50])	(19),	with	the	number	of	withdrawals	due	to	adverse	events	
being	applied	as	a	proxy	for	harm	(20).	Outcome	data	collection	was	at	6	months	if	possible	or	at	
the	time	point	closest	to	6	months	according	to	the	individual	trials.		ACR50	is	a	validated,	
clinically	meaningful,	binary	measure	of	benefit	(19);	for	safety,	we	chose	to	include	withdrawals	
due	to	adverse	events,	which	is	a	proxy	measure	for	patients’	tolerance	of	treatment	and	should	
be	reported	consistently	(20;21).	Other	outcomes	for	benefit	included	ACR20,	health	assessment	
questionnaire	(HAQ)	for	function,	and	radiographic	progression.	Safety	were	further	evaluated	
with	risk	of	serious	adverse	events	(SAE),	serious	infections,	and	gastrointestinal	adverse	events.	
For	each	trial,	we	collected:	type	and	doses	of	both	the	intervention	and	comparator	
(bDMARD	dose	was	categorized	according	to	the	product	labelling	as	recommended,	below	
recommended	[low]	or	above	recommended	dose	[high]);	study	duration;	disease	duration;	and	
whether	the	RA	population	was	MTX	naïve	or	experienced.	
Study	selection	and	data	extraction	were	done	independently	by	two	reviewers	(TSJ	&	ST).	
Disagreements	were	resolved	by	consensus	with	a	third	reviewer	(RC).	Internal	validity	was	
judged	independently	by	two	reviewers	(TSJ	&	ST),	using	the	Cochrane	Collaboration’s	risk-of-
bias	tool	(22).		
Synthesis	of	results	
Standard	pairwise	meta-analysis	was	performed	using	Review	Manager	(RevMan)	version	5.3.	
Meta-analysis	was	conducted	for	trials	comparing	a	bDMARD	in	combination	with	MTX	
(intervention)	vs.	bDMARD	monotherapy	(comparator).	In	cases	where	a	study	only	compared	
different	doses	of	MTX	in	combination	with	a	bDMARD,	the	meta-analysis	was	conducted	
comparing	the	highest	MTX-dose	with	the	lowest	MTX-dose	if	the	MTX	dose	in	the	comparator	
group	was	considered	very	low	(i.e.	below	10	mg).	Sensitivity	analysis	for	the	primary	outcomes	
where	conducted	to	analyse	the	impact	of	including	studies	comparing	different	MTX-doses.	
Dichotomous	outcomes	were	expressed	as	risk	ratios	(RR)	and	the	corresponding	95%	confidence	
intervals	(95%	CIs)	for	each	study.	For	continuous	variables,	net	differences	were	estimated	using	
the	standardised	mean	difference	(SMD)	with	95%	CI	for	each	study	(23).	
Evidence	synthesis	was	based	on	standard	inverse	variance	random	effects	for	meta-
analysis	(24).	We	tested	for	heterogeneity	with	the	Cochran’s	Q-test	and	used	the	method	
proposed	by	Higgins	et	al	to	measure	inconsistency,	I2,	i.e.,	the	percentage	of	total	variation	
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across	studies	due	to	heterogeneity	(25).	At	the	protocol	stage,	anticipating	important	
heterogeneity,	we	pre-specified	a	number	of	stratified	and	meta-regression	analyses,	stratifying	
the	available	studies	according	to	trial	characteristics	and	continuous	variables	at	study-level.	To	
explore	the	quantitative	impact	of	these	patient/trial	characteristics,	stratified	analyses	were	
performed.	Adalimumab,	golimumab,	infliximab,	and	rituximab	are	more	immunogenic	than	
other	bDMARDs	for	RA	and	anti-drug	antibody	formation	is	associated	with	reduced	clinical	
efficacy	(26).	For	these	agents	(except	rituximab)	concomitant	MTX	is	associated	with	lower	rates	
of	anti-drug	antibody	formation	(26).	Post	hoc	analyses	of	the	primary	outcomes	were	conducted	
to	explore	impact	of	these	known	differences	in	immunogenicity	(i.e.	adalimumab,	golimumab,	
infliximab,	and	rituximab	vs.	other	bDMARDs).	
Finally,	post	hoc	analyses	of	the	primary	outcomes	were	conducted	to	explore	efficacy	and	
safety	of	approved	Janus	kinase	(JAK)	inhibitors	(baricitinib	and	tofacitinib)	in	combination	with	
MTX	vs.		as	monotherapy.	Medline	(via	PubMed)	was	searched	for	published	RCTs	from	database	
inception	to	July	19,	2018	(Supplement	Table	2).	
GRADE	(Grading	of	Recommendations	Assessment,	Development	and	Evaluation)	was	
used	to	rate	the	overall	quality	of	the	evidence	for	each	outcome	based	on	risk	of	bias,	publication	
bias,	imprecision,	inconsistency,	indirectness,	and	magnitude	of	effect.	The	GRADE	ratings	of	
very	low–,	low-,	moderate-,	or	high-quality	evidence	reflecting	the	extent	to	which	we	are	
confident	that	the	true	effect	lies	close	to	that	of	the	estimate	of	the	effect	in	the	meta-analysis	
(27;28).	
	
RESULTS	
Searches	of	4	primary	electronic	databases	(Cochrane	Central	Register	of	Controlled	Trials,	
Medline,	Embase,	and	ClinicalTrials.gov)	and	reviews	identified	5,127	unique	references.	Of	the	
total,	675	underwent	full-text	review	and	23	references	were	included	in	the	final	review.	Of	these,	
3	references	were	excluded	from	the	meta-analysis:	2	had	a	bDMARD+MTX	run-in	period	before	
one	group	was	randomised	to	bDMARD	monotherapy	(29;30)	and	one	included	RA	patients	with	
hepatitis	C	(31).	Twenty	references	that	reported	16	unique	RCTs,	comparing	a	bDMARD	in	
combination	with	MTX	with	the	same	bDMARD	in	monotherapy,	proved	eligible	for	inclusion	in	
the	meta-analysis	(Figure	1).	All	approved	bDMARDs	except	anakinra	and	certolizumab	pegol	
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were	represented	among	the	included	trials.	Search	for	JAK	inhibitor	trials	returned	165	
references.	Of	these	2	unique	RCTs	were	eligible	for	inclusion.		
The	16	bDMARD	RCTs,	comprised	a	total	of	42	unique	trial-arms,	and	included	4,965	
patients	with	RA:	abatacept	(1	trial;	351	patients)(32),	adalimumab	(3	trials;	1,503	patients)(33-35),	
etanercept	(2	trials;	837	patients)(36;37),	golimumab	(3	trials;	1,724	patients)(38-40),	infliximab	(1	
trial;	105	patients)(41),	rituximab	(1	trial;	161	patients)(42),	and	tocilizumab	(5	trials;	2,519	
patients)(43-47)	(Table	1).	The	2	JAK	inhibitor	RCTs	included	1,134	patients	with	RA:	tofacitinib	(1	
trial;	760	patients)(48),	baricitinib	(1	trial;	374	patients)(49)	(Table	2).	
	
	 	
  
Benefit	and	harm	of	bDMARDs	according	to	major	outcomes	
The	GRADE	Evidence	Profile	(Figure	2)	includes	the	quality	of	the	available	evidence,	the	
judgments	that	bear	on	the	quality	rating,	and	the	combined	effect	sizes	of	interest	presented	
both	in	relative	and	absolute	terms	for	all	major	outcomes.	The	results	of	the	meta-analyses	for	
each	outcome	are	provided	in	Supplement	figure	1-8.	In	the	GRADE	approach,	RCTs	start	as	
high-quality	evidence	supporting	estimates	of	intervention	effects.	However,	as	illustrated	in	
Figure	2,	five	factors	may	lead	to	rating	down	the	quality	of	evidence.	Ultimately,	the	quality	of	
evidence	for	each	outcome	was	either	moderate	or	low.	
	
ACR50	response	
After	on	average	6	months	ACR50	response	was	statistically	significantly	in	favour	of	
concomitant	use	of	MTX	compared	to	bDMARD	monotherapy	(RR=1.32	[95%CI:	1.20	to	1.45],	
with	a	small-to-moderate	degree	of	inconsistency	[I2=39%;	P=0.04])	(Supplement	figure	1).	In	
absolute	terms	this	corresponds	to	11	(95%CI:	7	to	16)	extra	patients	out	of	100	patients	treated	
who	will	achieve	the	ACR50	goal	due	to	concomitant	MTX.	The	analysis	indicated	that	the	added	
value	of	MTX	varied	with	the	choice	of	bDMARD	(Test	for	subgroup	differences	P=0.07);	a	
subgroup	difference	likely	driven	by	infliximab	(3.54	[1.38	to	9.08]).	It	was	decided	to	rate	down	(-
1)	our	confidence	in	the	estimate	to	Moderate	Quality	Evidence,	due	to	heterogeneity	of	possible	
importance	(test	for	homogeneity,	P=0.04).	When	excluding	comparisons	not	evaluating	
recommended	dose	of	bDMARD	or	a	MTX	dose	below	10	mg	heterogeneity	was	reduced	and	not	
statistically	significant	(I2=21%;	P=0.24)	with	no	apparent	influence	in	the	overall	estimate	(1.30	
[1.20	to	1.41]	(Supplement	figure	9).	When	excluding	comparisons	evaluating	different	doses	of	
MTX	heterogeneity	was	increased	and	statistical	significant	(I2=45%;	P=0.02)	though	with	no	
apparent	influence	in	the	overall	estimate	(1.33	[1.20	to	1.48]	(Supplement	figure	10).	When	
stratifying	by	immunogenicity	(high	immunogenic	[adalimumab,	golimumab,	infliximab,	and	
rituximab]	vs.	low	immunogenic	[other	bDMARDs])	the	analysis	indicated	no	differences	(Test	for	
subgroup	differences	P=0.09)	(Supplement	figure	11).	
	
Withdrawal	due	to	adverse	events	
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The	overall	estimate	of	discontinuing	therapy	due	to	adverse	events	from	concomitant	use	of	
MTX	was	1.20	[0.96	to	1.49]	compared	to	bDMARD	monotherapy	-	corresponding	to	a	possible	
20%	increased	risk	(P=0.09;	I2=0%)	(Supplement	figure	2).	Although	not	statistically	significant,	
this	relative	effect	would	potentially	translate	into	1	patient	out	of	100	patients	treated	who	will	
discontinue	therapy	due	to	adverse	events	from	MTX.	There	was	no	statistical	signal	suggesting	a	
difference	between	the	different	bDMARDs	(Test	for	subgroup	differences	P=0.43).	It	was	
decided	to	rate	down	(-1)	our	confidence	in	the	estimate	to	Moderate	Quality	Evidence,	because	
of	the	imprecision	(low	statistical	power	to	detect	a	difference)	around	the	pooled	relative	
estimate	(95%CI:	0.96	to	1.49).	Excluding	comparisons	not	evaluating	recommended	dose	of	
bDMARD	or	a	MTX	dose	below	10	mg	heterogeneity	had	no	apparent	influence	in	the	overall	
estimate	(1.23	[0.96	to	1.58];	I2=0%)	(Supplement	figure	12).	Excluding	comparisons	evaluating	
different	doses	of	MTX	did	not	influence	the	overall	estimate	(1.21	[0.97	to	1.53];	I2=0%)	
(Supplement	figure	13).	When	stratifying	by	immunogenicity	(high	immunogenic	[adalimumab,	
golimumab,	infliximab,	and	rituximab]	vs.	low	immunogenic	[other	bDMARDs])	the	analysis	
indicated	no	differences	(Test	for	subgroup	differences	P=0.74)	(Supplement	figure	14).	
	
ACR20	response	
The	overall	likelihood	of	achieving	an	ACR20	responding	was	1.20	(1.12	to	1.29)	–	with	
considerable	inconsistency	(I2=61%)	-	in	favour	of	concomitant	use	of	MTX	when	treated	with	a	
bDMARD	(Supplement	figure	3);	corresponding	to	12	(7	to	17)	extra	patients	out	of	100	patients	
treated	who	will	achieve	the	ACR20	goal	due	to	MTX.	However,	due	to	the	important	difference	
among	bDMARDs	(i.e.	reason	to	suspect	that	the	added	value	of	MTX	varies	with	the	choice	of	
bDMARD	[Test	for	subgroup	differences	P=0.01])	we	decided	to	rate	down	(-2)	our	confidence	in	
the	estimate	to	Low	Quality	Evidence	for	very	serious	inconsistency.	When	excluding	
comparisons	not	evaluating	recommended	dose	of	bDMARD	or	a	MTX	dose	below	10	mg	
heterogeneity	was	reduced	and	not	statistically	significant	(I2=	44%;	P	=	0.06)	along	with	no	
statistically	significant	difference	among	bDMARDs	(Test	for	subgroup	differences	P=0.07)	with	
only	limited	influence	in	the	overall	estimate	(1.12	[1.06	to	1.20]	(Supplement	figure	15).	
	
Function	
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difference	between	the	different	bDMARDs	concerning	risk	of	serious	infections	(Test	for	
subgroup	differences	P	=	0.16).	
	
Gastrointestinal	adverse	events	
Risk	of	gastrointestinal	adverse	events	(i.e.	nausea)	was	65%	higher	with	concomitant	use	of	MTX	
(1.65	[1.27	to	2.14])	corresponding	to	6	(3	to	11)	more	patient	out	of	100	patients	treated	will	
experience	gastrointestinal	adverse	events	due	to	MTX	(Supplement	figure	8).	Due	to	the	
important	heterogeneity	(I2=	46%;	p=0.04),	difference	among	bDMARDs	(Test	for	subgroup	
differences	p=0.009),	and	reporting	bias	we	decided	to	rate	down	(-2)	our	confidence	in	the	
estimate	to	Low	Quality	Evidence.	
	
Benefit	and	harm	of	JAK	inhibitors	according	to	primary	outcomes		
After	6	months	ACR50	response	was	not	statistically	significantly	different	between	concomitant	
use	of	MTX	compared	to	JAK	inhibitor	monotherapy	(1.13	[0.99	to	1.28]),	with	a	low	degree	of	
inconsistency	[I2=11%]	(Supplement	Figure	16).	In	absolute	terms	this	corresponds	to	6	(0	to	12)	
extra	patients	out	of	100	patients	treated	will	achieve	the	ACR50	goal	due	to	MTX.	There	was	no	
significant	difference	between	the	two	different	JAK	inhibitors	(Test	for	subgroup	differences	
P=0.29).	It	was	decided	to	rate	down	(-1)	our	confidence	in	the	estimate	to	Moderate	Quality	
Evidence,	due	to	imprecision.  
The	overall	estimate	of	discontinuing	therapy	due	to	adverse	events	from	concomitant	use	of	
MTX	compared	to	JAK	inhibitor	monotherapy	was	not	statistically	significantly	increased	(1.30	
[0.82	to	2.08];	P=0.27;	I2=0%)	(Supplement	Figure	17).	There	was	no	statistical	signal	suggesting	
a	difference	between	the	two	JAK	inhibitors	(Test	for	subgroup	differences	P=0.39).	It	was	
decided	to	rate	down	(-1)	our	confidence	in	the	estimate	to	Moderate	Quality	Evidence,	because	
of	the	imprecision.		
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DISCUSSION	
To	our	knowledge,	this	is	the	first	systematic	review	with	evidence	synthesis	comparing	the	value	
of	adding	MTX	to	a	bDMARD	compared	to	bDMARD	monotherapy	when	evaluating	the	efficacy	
and	safety	in	patients	with	RA.	When	combining	trial	data,	we	found	evidence	indicating	
moderate	to	low	confidence	in	the	estimates	that	combining	the	prescribed	bDMARD	with	MTX	
improves	the	effectiveness	of	the	bDMARD.	The	present	meta-analysis	suggests	that	using	a	
bDMARD	in	combination	with	MTX	increases	the	possibility	of	achieving	an	ACR50	by	32%	
compared	to	bDMARD	monotherapy.	In	addition	to	the	apparent	benefit	of	using	MTX	
concomitantly	with	a	bDMARD,	some	unwanted	effects	may	occur	e.g.	gastrointestinal	adverse	
events.	Also,	our	analysis	revealed	combining	MTX	with	a	bDMARD	appears	to	increase	the	risk	of	
discontinuing	therapy	due	to	unwanted	side	effects	(a	potential	20%	increased	risk).	Moreover,	
the	analyses	showed	infliximab	being	the	bDMARD	most	dependent	on	concomitant	use	of	MTX	
for	achieving	clinical	efficacy.	The	efficacy	and	safety	of	JAK	inhibitors	(baricitinib	and	tofacitinib),	
was	evaluated	in	a	post	hoc	analysis.	With	moderate	quality	evidence	we	found	that	JAK	inhibitors	
as	a	class	were	more	effective	in	combination	with	MTX	compared	as	monotherapy	although	the	
ACR50	estimate	was	not	statistical	significant.		
According	to	the	EULAR	guidelines	and	ACR	recommendations,	based	on	its	
established	efficacy	and	safety	(2;3),	MTX	is	the	appropriate	first-line	DMARD	for	treating	active	
RA either	administrated	orally	or	subcutaneously	at	a	tolerated	dose.	If	gastric	issues	arise	from	
oral	MTX	a	switch	to	injectable	MTX	may	be	a	relevant	option.	It	has	been	estimated	that	MTX	
monotherapy	achieves	satisfactory	disease	control	in	only	approximately	one-third	of	patients	
and	that	two-thirds	of	patients	requiring	more	active	therapy	which	may	include	addition	of	a	
bDMARD	(2;3).	Further,	international	guidelines	state	that	monotherapy	with	a	bDMARD	should	
be	a	treatment	option	for	patients	with	RA	only	when	they	have	toxicities	to,	or	are	intolerant	of,	
MTX	and	other	csDMARDs	(2;3).		
The	empirical	evidence	from	this	systematic	review	clearly	demonstrated	improved	
efficacy	of	concomitant	MTX	compared	to	bDMARD	monotherapy.	These	findings	are	consistent	
with	observations	from	the	CONCERTO	trial	that	demonstrated	increasing	doses	of	MTX	in	
combination	with	adalimumab	resulted	in	improved	clinical	outcomes	(35).	
An	observational	study	showed	that,	in	Denmark,	close	to	one	in	five	bDMARD	
treatments	for	RA	were	prescribed	as	monotherapy	(50).	Of	these,	70%	were	on	monotherapy	
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from	bDMARD	therapy	initiation	and	30%	were	on	monotherapy	after	cessation	of	concomitant	
csDMARDs.	Apart	from	infliximab,	there	was	no	statistically	significant	difference	between	the	
various	bDMARDs	in	remission	rates	and	drug	adherence	in	patients	treated	with	a	bDMARD	in	
monotherapy	(50).	The	better	performance	of	infliximab	when	added	to	MTX	was	expected,	since	
infliximab	is	not	recommended	or	approved	as	monotherapy	(51).	Thus,	the	patients	who	
received	infliximab	as	monotherapy	were	likely	to	be	a	highly	selected	subgroup	(50).	 	
Our	evidence	synthesis	also	has	limitations.	The	included	16	bDMARD	studies	span	
an	18-year	period,	from	1998	through	2016;	so,	patients	enrolled	in	early	studies	may	differ	from	
those	included	in	more	recent	studies.	Moreover,	the	RA	patients	enrolled	in	the	different	studies	
are	to	some	extent	heterogeneous	(encompassing	different	duration	of	diseases	and	differences	
in	the	extent	of	prior	MTX	failure).	Further,	we	were	not	able	to	include	anakinra	and	certolizumab	
pegol	in	the	analysis.	The	time	points	at	which	ACR50	was	assessed	in	the	16	studies	included	in	
our	analysis	varied	from	16-52	weeks	(14	trials	24-26	weeks;	on	average	26	weeks).	Therefore,	
whether	our	results	can	be	extrapolated	to	longer-term	efficacy	and	safety	is	not	clear.	This	may	
also	be	of	relevance	to	interpreting	our	findings	as	one	potential	reason	for	improved	efficacy	
observed	when	MTX	is	given	concomitantly	with	bDMARD	is	that	MTX	may	diminish	the	
immunogenicity	of	the	administered	bDMARD.	However,	other	synergistic	mechanisms	of	action	
may	also	contribute	(14).	Finally,	there	remains	a	certain	amount	of	reporting	bias	with	MTX	
consumption	at	the	side	of	the	patients,	which	may	not	adhere	to	the	prescriptions	(15)	and	the	
actual	percentage	of	patients	remaining	in	combination	therapy	with	bDMARDs	and	MTX	may	be	
lower	than	the	numbers	stated	in	the	registries. 	
In	conclusion,	in	the	management	of	RA,	evidence	from	RCTs	supports	the	added	
value	for	efficacy	of	combining	the	prescribed	bDMARD	with	the	concomitant	use	of	MTX	as	
recommended	in	current	clinical	practice.	Although	the	precision	around	the	estimate	of	
concomitant	MTX	use	does	not	rule	out	an	increased	risk	of	clinically	important	harm,	the	efficacy	
findings	justify	the	recommendation	that	all	patients	prescribed	bDMARD	should	be	encouraged	
to	continue	MTX	therapy	although	in	absolute	terms	only	7	to	16	more	out	of	100	patients	will	
achieve	an	ACR50	response	after	6	months	of	therapy.	
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Figure	legends:	
	
Figure	1:	Study	selection		
Legend:	RCT	=	randomised	controlled	trial;	bDMARD	=	biologic	disease-modifying	anti-rheumatic	
drug;	RA	=	rheumatoid	arthritis;	MTX	=	methotrexate.	
	
	
Figure	2:	GRADE	Evidence	Profile	
Legend:	ACR	=	American	College	of	Rheumatology	criteria	[ACR20:	50%	improvement;	ACR50:	
50%	improvement);	HAQ	=	health	assessment	questionnaire	for	function;	CI	=	confidence	
interval;	RR	=	risk	ratio;	SMD	=	standardised	mean	difference;	bDMARD	=	biologic	disease-
modifying	anti-rheumatic	drug;	MTX	=	methotrexate.		
a.	Statistically	significant	heterogeneity	P	=	0.04	(I²	=	39%);	b:	Lower	limit	of	CI	indicate	no	
differences	(P=0.09);	c:	Statistically	significant	heterogeneity	and	statistically	significant	
differences	among	bDMARDs;	d:	Three	bDMARDs	were	not	represented	in	the	analysis	
(abatacept,	infliximab	and	rituximab);	e:	Infliximab	was	not	included	in	the	analysis	due	to	lack	of	
reporting;	f:	Not	statistically	significant.	Based	on	the	lower	and	upper	confidence	limits	a	
potential	increased	or	decreased	risk	of	the	addition	of	MTX	could	not	be	ruled	out;	g:	Reporting	
bias.	
  
Table	1:	Study	characteristics	of	included	biological	disease-modifying	anti-rheumatic	drug	trials	
Study	information	 bDMARD§	 MTX	intervention	 MTX	comparator	
Risk	of	bias†	
Author	 Acronym	 Duration*	
(weeks)	
Disease	
duration	
(years)	
MTX	
history	
Drug	 Dose	
mg.	
Dose	
cat.	
Dose	
mg.	
No.	
pts.	
MTX	
dose	
mg.	
No	
pts.	
Emery(32)	 AVERT	 24/52	 0.6	 Naïve¶	 ABA	 125	QW	 R	 15-20	 119	 0	 116	 L,L,L,L,L,L	
Breedveld(34)	 PREMIER	 52/104	 0.7	 Naïve	 ADA	 40	Q2W	 R	 20**	 268	 0	 274	 L,L,L,L,L,L	
Burmester(35)	 CONCERTO	 26/26	 0.3	 Naïve	 ADA	 40	Q2W	 R	 20	 98	 2.5	 98	 L,L,L,L,L,L	
Kaeley(33)	 MUSICA	 24/24	 5.3	 Exp.	 ADA	 40	Q2W	 R	 20	 155	 7.5	 154	 L,L,H,H,L,L	
Klareskog(37)	 TEMPO	 24/52	 6.5	 Naïve/Exp.	 ETA	 25	BIW	 R	 20**	 229	 0	 228	 L,L,L,L,L,L	
Kameda(36)	 JESMR	 24/24	 9.3	 Exp.	 ETA	 25	BIW	 R	 8	 77	 0	 74	 L,L,H,H,L,H	
Emery(38)	 GOBEFORE	 24/24	 3.9	 Naïve	 GOL	 100	Q4W	 H	 20**	 159	 0	 159	 L,L,L,L,L,L	
Keystone(39)	 GOFORWARD	 24/24	 6.3	 Exp.	 GOL	 100	Q4W	 H	 15-25	 89	 0	 133	 L,L,L,L,L,L	
Kremer(40)	 GOLIVE	 24/16	 8.3	 Exp.	 GOL	
2/kg	Q12W	 R	
15-25	
129	
0	
128	
L,L,L,L,L,H	
4/kg	Q12W	 H	 128	 129	
Maini(41)	 	 26/14	 10.4	 Exp.	 INF	
1	x	5††	 L	
7.5	
14	
0	
15	
L,L,L,L,L,L	3	x	5††	 H	 15	 14	
10	x	5††	 H	 14	 15	
Edwards(42)	 	 24/24	 10.5	 Exp.	 RIT	 1000	x	2§§	 R	 ≥10	 40	 0	 40	 L,L,L,L,L,L	
Maini(47)	 CHARISMA	 16/20	 0.8	 Exp.	 TOC	
2/kg	Q4W	 L	
10-25	
52	
0	
53	
L,L,L,L,L,H	4/kg	Q4W	 L	 49	 54	
8/kg	Q4W	 R	 50	 52	
Dougados(45)	 ACT-RAY	 24/24	 8.3	 Exp.	 TOC	 8/kg	Q4W	 R	 ≥15	 279	 0	 277	 L,L,L,L,L,L	
Burmester(44)	 FUNCTION	 24/52	 0.5	 Naïve	 TOC	 8/kg	Q4W	 R	 20**	 291	 0	 292	 L,L,L,L,L,L	
Kaneko(46)	 SURPRISE	 24/52	 3.7	 Exp.	 TOC	 8/kg	Q4W	 R	 8.6	 118	 0	 115	 L,U,H,H,L,L	
Bijlsma(43)	 U-ACT-EARLY	 24/104	 0.1	 Naïve	 TOC	 8/kg	Q4W	 R	 30**	 106	 0	 103	 L,L,L,L,L,L	
Exp.	=	experienced;	bDMARD	=	biological	DMARDs;	NR	=	not	reported;	QW	=	every	week;	Q2W	=	every	2	weeks;	Q4W	=	every	4	weeks;	Q12W	=	every	12	weeks;	BIW	=	
twice	a	week;	Dose	cat.	=	dose	category	[L=	below	recommended,	R=recommended	dose,	H=above	recommended];	ABA	=	abatacept;	ADA	=	adalimumab;	ETA	=	
etanercept;	GOL	=	golimumab;	INF	=	infliximab;	RIT	=	rituximab;	TOC	=	tocilizumab;	MTX	=	methotrexate.	†:	Risk	of	Bias:	Random	sequence	generation	(selection	bias),	
Allocation	concealment	(selection	bias),	Blinding	of	participants	and	personnel	(performance	bias),	Blinding	of	outcome	assessment	(detection	bias),	Incomplete	outcome	
data,	Selective	reporting	(reporting	bias).	L	=	Low	risk	of	bias.	U	=	unclear	risk	of	bias.	H	=	high	risk	of	bias.	*:	benefit/harm.	**:	maximum	end	dose	if	titration	regime	was	
necessary.	§:	In	all	individual	trials	bDMARD	and	dose	were	the	same	in	the	intervention	and	comparator	groups.	¶:	MTX	naïve	or	receiving	less	than	10	mg/week	for	≤	4	
weeks	with	no	MTX	for	1	month	prior	to	screening.	††:	on	week	0,	2,	6,	10,	and	14.	§§:	on	day	1	and	15.	
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Table	2:	Study	characteristics	of	included	Janus	kinase	inhibitor	trials	
Study	information	 JAK	inhibitor§	 MTX	intervention	 MTX	comparator	
Risk	of	bias†	
Author	 Acronym	 Duration*	
(weeks)	
Disease	
duration	
(years)	
MTX	
history	
Drug	 Dose	
mg.	
Dose	
cat.	
Dose	
mg.	
No.	
pts.	
MTX	
dose	
mg.	
No	
pts.	
Fleischmann	
(48)	
ORAL	Strategy	 24/52	 5.8	 Exp.	 TOF	 5	BD	 R	 15-25	 376	 0	 384	 L,L,L,L,L,L	
Fleischmann	
(49)	
RA-BEGIN	 24/24	 0.7	 Naïve¶	 BAR	 4	OD	 R	 20**	 215	 0	 159	 L,L,L,L,L,L	
Exp.	=	experienced;	BD	=	twice	daily;	OD	=	once	daily;	JAK	=	Janus	kinase;	TOF	=	tofacitinib;	BAR	=	baricitinib	MTX	=	methotrexate;	Dose	cat.	=	dose	category	[L=	below	
recommended,	R=recommended	dose,	H=above	recommended].	*:	benefit/harm.	§:	In	all	individual	trials	JAK	inhibitor	and	dose	were	the	same	in	the	intervention	and	
comparator	groups.	†:	Risk	of	Bias:	Random	sequence	generation	(selection	bias),	Allocation	concealment	(selection	bias),	Blinding	of	participants	and	personnel	
(performance	bias),	Blinding	of	outcome	assessment	(detection	bias),	Incomplete	outcome	data,	Selective	reporting	(reporting	bias).	L	=	Low	risk	of	bias.	U	=	unclear	risk	of	
bias.	H	=	high	risk	of	bias.	¶:	up	to	3	weekly	MTX	doses	permitted.	**:	maximum	end	dose	if	titration	regime	was	necessary.		
	 	
